Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.99
EGRX's Cash-to-Debt is ranked higher than
98% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. EGRX: 1.99 )
Ranked among companies with meaningful Cash-to-Debt only.
EGRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.77  Med: No Debt Max: No Debt
Current: 1.99
Equity-to-Asset 0.64
EGRX's Equity-to-Asset is ranked higher than
70% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. EGRX: 0.64 )
Ranked among companies with meaningful Equity-to-Asset only.
EGRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -9.9  Med: 0.72 Max: 0.8
Current: 0.64
-9.9
0.8
Debt-to-Equity 0.29
EGRX's Debt-to-Equity is ranked lower than
99.99% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. EGRX: 0.29 )
Ranked among companies with meaningful Debt-to-Equity only.
EGRX' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.09  Med: 0.1 Max: 0.29
Current: 0.29
-0.09
0.29
Debt-to-EBITDA 0.51
EGRX's Debt-to-EBITDA is ranked lower than
99.99% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. EGRX: 0.51 )
Ranked among companies with meaningful Debt-to-EBITDA only.
EGRX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.43  Med: -0.43 Max: 0.51
Current: 0.51
-0.43
0.51
Interest Coverage 154.08
EGRX's Interest Coverage is ranked higher than
60% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 106.84 vs. EGRX: 154.08 )
Ranked among companies with meaningful Interest Coverage only.
EGRX' s Interest Coverage Range Over the Past 10 Years
Min: 154.08  Med: 3450.81 Max: 6668.88
Current: 154.08
154.08
6668.88
Piotroski F-Score: 7
Altman Z-Score: 8.27
Beneish M-Score: -1.08
WACC vs ROIC
7.53%
97.34%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 33.88
EGRX's Operating Margin % is ranked higher than
95% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. EGRX: 33.88 )
Ranked among companies with meaningful Operating Margin % only.
EGRX' s Operating Margin % Range Over the Past 10 Years
Min: -781.06  Med: -61.81 Max: 33.88
Current: 33.88
-781.06
33.88
Net Margin % 36.95
EGRX's Net Margin % is ranked higher than
96% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. EGRX: 36.95 )
Ranked among companies with meaningful Net Margin % only.
EGRX' s Net Margin % Range Over the Past 10 Years
Min: -763.41  Med: -44.21 Max: 42.99
Current: 36.95
-763.41
42.99
ROE % 65.89
EGRX's ROE % is ranked higher than
98% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. EGRX: 65.89 )
Ranked among companies with meaningful ROE % only.
EGRX' s ROE % Range Over the Past 10 Years
Min: 4.17  Med: 35.81 Max: 67.44
Current: 65.89
4.17
67.44
ROA % 46.68
EGRX's ROA % is ranked higher than
99% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. EGRX: 46.68 )
Ranked among companies with meaningful ROA % only.
EGRX' s ROA % Range Over the Past 10 Years
Min: -205.37  Med: -43.92 Max: 48.07
Current: 46.68
-205.37
48.07
ROC (Joel Greenblatt) % 218.95
EGRX's ROC (Joel Greenblatt) % is ranked higher than
98% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. EGRX: 218.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
EGRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5164.61  Med: -1476.75 Max: 359.13
Current: 218.95
-5164.61
359.13
3-Year Revenue Growth Rate 36.90
EGRX's 3-Year Revenue Growth Rate is ranked higher than
93% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. EGRX: 36.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
EGRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 36.9  Med: 37.65 Max: 38.4
Current: 36.9
36.9
38.4
GuruFocus has detected 3 Warning Signs with Eagle Pharmaceuticals Inc EGRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EGRX's 30-Y Financials

Financials (Next Earnings Date: 2018-03-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

EGRX Guru Trades in Q4 2016

Joel Greenblatt 87,429 sh (+121.46%)
First Eagle Investment 634,805 sh (+11.72%)
Ken Fisher 5,780 sh (-39.48%)
» More
Q1 2017

EGRX Guru Trades in Q1 2017

Joel Greenblatt 145,012 sh (+65.86%)
Ken Fisher 7,680 sh (+32.87%)
First Eagle Investment 661,005 sh (+4.13%)
» More
Q2 2017

EGRX Guru Trades in Q2 2017

Ken Heebner 25,000 sh (New)
Steven Cohen 45,750 sh (New)
Ken Fisher 11,045 sh (+43.82%)
Joel Greenblatt 175,214 sh (+20.83%)
First Eagle Investment 651,505 sh (-1.44%)
» More
Q3 2017

EGRX Guru Trades in Q3 2017

Chuck Royce 67,916 sh (New)
Ken Fisher 23,921 sh (+116.58%)
Joel Greenblatt 177,136 sh (+1.10%)
Steven Cohen Sold Out
Ken Heebner Sold Out
First Eagle Investment 601,505 sh (-7.67%)
» More
» Details

Insider Trades

Latest Guru Trades with EGRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
First Eagle Investment 2017-09-30 Reduce -7.67%0.01%$46.62 - $83.48 $ 56.85-7%601,505
Joel Greenblatt 2017-09-30 Add 1.10%$46.62 - $83.48 $ 56.85-7%177,136
Ken Fisher 2017-09-30 Add 116.58%$46.62 - $83.48 $ 56.85-7%23,921
Ken Heebner 2017-09-30 Sold Out 0.09%$46.62 - $83.48 $ 56.85-7%0
First Eagle Investment 2017-06-30 Reduce -1.44%$69.28 - $96.85 $ 56.85-31%651,505
Joel Greenblatt 2017-06-30 Add 20.83%0.03%$69.28 - $96.85 $ 56.85-31%175,214
Ken Heebner 2017-06-30 New Buy0.09%$69.28 - $96.85 $ 56.85-31%25,000
Ken Fisher 2017-06-30 Add 43.82%$69.28 - $96.85 $ 56.85-31%11,045
First Eagle Investment 2017-03-31 Add 4.13%0.01%$62.83 - $84.92 $ 56.85-24%661,005
Joel Greenblatt 2017-03-31 Add 65.86%0.06%$62.83 - $84.92 $ 56.85-24%145,012
Ken Fisher 2017-03-31 Add 32.87%$62.83 - $84.92 $ 56.85-24%7,680
First Eagle Investment 2016-12-31 Add 11.72%0.01%$55.88 - $84.22 $ 56.85-22%634,805
Joel Greenblatt 2016-12-31 Add 121.46%0.05%$55.88 - $84.22 $ 56.85-22%87,429
Ken Fisher 2016-12-31 Reduce -39.48%$55.88 - $84.22 $ 56.85-22%5,780
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NYSE:LCI, TSX:LEAF, NAS:HRTX, TSX:ACB, BOM:530549, SZSE:000597, NAS:AMPH, SHSE:600530, SZSE:300086, SHSE:603669, TSE:4553, BOM:540222, HKSE:02877, TPE:1789, SHSE:603168, TPE:1707, SZSE:300436, TSX:APH, ADX:JULPHAR, SHSE:603998 » details
Traded in other countries:1E6.Germany,
Headquarter Location:USA
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology.

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, docetaxel injection, non-alcohol formulation and Bendeka. The company currently have multiple product candidates in advanced stages of development, and under review for approval by the Food and Drug Administration.

Guru Investment Theses on Eagle Pharmaceuticals Inc

First Eagle Fund of America Comments on Eagle Pharmaceuticals - Oct 31, 2017

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) fell after the FDA denied approval for the company’s lead drug, Ryanodex, for a new indication—exertional heat stroke (EHS). The drug is currently marketed for malignant hypothermia, and the company continues to conduct trials for other indications while holding further discussions with the FDA about the drug’s potential for EHS. The market appears to ascribe little value to any future indications, but we see the potential for upside if any are approved.



From First Eagle Fund of America third quarter 2017 shareholder commentary.



Check out First Eagle Investment latest stock trades

Top Ranked Articles about Eagle Pharmaceuticals Inc

First Eagle Fund of America Comments on Eagle Pharmaceuticals Guru stock highlight
Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) fell after the FDA denied approval for the company’s lead drug, Ryanodex, for a new indication—exertional heat stroke (EHS). The drug is currently marketed for malignant hypothermia, and the company continues to conduct trials for other indications while holding further discussions with the FDA about the drug’s potential for EHS. The market appears to ascribe little value to any future indications, but we see the potential for upside if any are approved. Read more...
Value Investors' Favorite Drug Companies Missed earnings expectations for second-quarter prompted price drops for most
All portfolios of gurus tracked by GuruFocus for the second quarter have been turned in, enabling the S&P 500 screener to sift out the drug company stocks that they bought the most. Read more...
Largest Insider Buys and Sells of the Week Pharmaceutical, insurance and financial companies top the list
The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+,” the duration to “March 2017” and All Insider Sales to “$5,000,000+.” Read more...
Director of Eagle Pharmaceuticals Buys Shares Company's stock has risen by an estimated 113% over the previous year
Eagle Pharmaceuticals (NASDAQ:EGRX) Director Richard Edlin bought 6,000 shares for $79.44 per share on March 22, according to the Securities and Exchange Commission. Read more...

Ratios

vs
industry
vs
history
PE Ratio 9.20
EGRX's PE Ratio is ranked higher than
91% of the 570 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.41 vs. EGRX: 9.20 )
Ranked among companies with meaningful PE Ratio only.
EGRX' s PE Ratio Range Over the Past 10 Years
Min: 8.06  Med: 15.13 Max: 462.71
Current: 9.2
8.06
462.71
Forward PE Ratio 13.48
EGRX's Forward PE Ratio is ranked higher than
70% of the 74 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.53 vs. EGRX: 13.48 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 9.20
EGRX's PE Ratio without NRI is ranked higher than
92% of the 566 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.56 vs. EGRX: 9.20 )
Ranked among companies with meaningful PE Ratio without NRI only.
EGRX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.06  Med: 15.13 Max: 462.71
Current: 9.2
8.06
462.71
Price-to-Owner-Earnings 10.96
EGRX's Price-to-Owner-Earnings is ranked higher than
91% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.43 vs. EGRX: 10.96 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
EGRX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.23  Med: 10.28 Max: 11.6
Current: 10.96
6.23
11.6
PB Ratio 4.93
EGRX's PB Ratio is ranked lower than
76% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. EGRX: 4.93 )
Ranked among companies with meaningful PB Ratio only.
EGRX' s PB Ratio Range Over the Past 10 Years
Min: 2.94  Med: 7.3 Max: 17.09
Current: 4.93
2.94
17.09
PS Ratio 3.37
EGRX's PS Ratio is ranked lower than
59% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. EGRX: 3.37 )
Ranked among companies with meaningful PS Ratio only.
EGRX' s PS Ratio Range Over the Past 10 Years
Min: 1.7  Med: 7.76 Max: 28.43
Current: 3.37
1.7
28.43
Price-to-Free-Cash-Flow 13.21
EGRX's Price-to-Free-Cash-Flow is ranked higher than
72% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.72 vs. EGRX: 13.21 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
EGRX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.99  Med: 32.54 Max: 232.79
Current: 13.21
11.99
232.79
Price-to-Operating-Cash-Flow 12.64
EGRX's Price-to-Operating-Cash-Flow is ranked higher than
68% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.64 vs. EGRX: 12.64 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
EGRX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.96  Med: 22.95 Max: 229.12
Current: 12.64
9.96
229.12
EV-to-EBIT 8.70
EGRX's EV-to-EBIT is ranked higher than
81% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. EGRX: 8.70 )
Ranked among companies with meaningful EV-to-EBIT only.
EGRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -358.9  Med: 9.05 Max: 650.1
Current: 8.7
-358.9
650.1
EV-to-EBITDA 8.40
EGRX's EV-to-EBITDA is ranked higher than
75% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. EGRX: 8.40 )
Ranked among companies with meaningful EV-to-EBITDA only.
EGRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -364.3  Med: 8.75 Max: 621.6
Current: 8.4
-364.3
621.6
EV-to-Revenue 2.95
EGRX's EV-to-Revenue is ranked lower than
53% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. EGRX: 2.95 )
Ranked among companies with meaningful EV-to-Revenue only.
EGRX' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.4  Med: 7.3 Max: 27.6
Current: 2.95
1.4
27.6
Current Ratio 5.30
EGRX's Current Ratio is ranked higher than
68% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. EGRX: 5.30 )
Ranked among companies with meaningful Current Ratio only.
EGRX' s Current Ratio Range Over the Past 10 Years
Min: 0.42  Med: 3.49 Max: 5.3
Current: 5.3
0.42
5.3
Quick Ratio 5.15
EGRX's Quick Ratio is ranked higher than
72% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. EGRX: 5.15 )
Ranked among companies with meaningful Quick Ratio only.
EGRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.42  Med: 3.29 Max: 5.15
Current: 5.15
0.42
5.15
Days Inventory 24.99
EGRX's Days Inventory is ranked higher than
92% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. EGRX: 24.99 )
Ranked among companies with meaningful Days Inventory only.
EGRX' s Days Inventory Range Over the Past 10 Years
Min: 2.15  Med: 20.16 Max: 190.54
Current: 24.99
2.15
190.54
Days Sales Outstanding 96.41
EGRX's Days Sales Outstanding is ranked lower than
55% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. EGRX: 96.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
EGRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 81.28  Med: 139.43 Max: 227.28
Current: 96.41
81.28
227.28
Days Payable 52.16
EGRX's Days Payable is ranked higher than
52% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. EGRX: 52.16 )
Ranked among companies with meaningful Days Payable only.
EGRX' s Days Payable Range Over the Past 10 Years
Min: 52.16  Med: 97.12 Max: 166.48
Current: 52.16
52.16
166.48

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -71.40
EGRX's 3-Year Average Share Buyback Ratio is ranked lower than
95% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. EGRX: -71.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EGRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -111.5  Med: -91.45 Max: -71.4
Current: -71.4
-111.5
-71.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 473.75
EGRX's Price-to-Net-Cash is ranked lower than
100% of the 234 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.00 vs. EGRX: 473.75 )
Ranked among companies with meaningful Price-to-Net-Cash only.
EGRX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 5.02  Med: 17.22 Max: 1972.25
Current: 473.75
5.02
1972.25
Price-to-Net-Current-Asset-Value 9.82
EGRX's Price-to-Net-Current-Asset-Value is ranked lower than
74% of the 474 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.23 vs. EGRX: 9.82 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
EGRX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.03  Med: 10.14 Max: 26.45
Current: 9.82
4.03
26.45
Price-to-Tangible-Book 7.90
EGRX's Price-to-Tangible-Book is ranked lower than
83% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. EGRX: 7.90 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EGRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4  Med: 8.15 Max: 15.56
Current: 7.9
4
15.56
Price-to-Median-PS-Value 0.43
EGRX's Price-to-Median-PS-Value is ranked higher than
92% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. EGRX: 0.43 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EGRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.3  Med: 0.88 Max: 3.07
Current: 0.43
0.3
3.07
Price-to-Graham-Number 1.80
EGRX's Price-to-Graham-Number is ranked lower than
54% of the 438 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.97 vs. EGRX: 1.80 )
Ranked among companies with meaningful Price-to-Graham-Number only.
EGRX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.78  Med: 3.32 Max: 16.99
Current: 1.8
1.78
16.99
Earnings Yield (Greenblatt) % 11.51
EGRX's Earnings Yield (Greenblatt) % is ranked higher than
87% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. EGRX: 11.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EGRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -21.2  Med: 0.2 Max: 12
Current: 11.51
-21.2
12

More Statistics

Revenue (TTM) (Mil) $271.06
EPS (TTM) $ 6.18
Beta0.86
Short Percentage of Float43.07%
52-Week Range $45.05 - 97.15
Shares Outstanding (Mil)14.92

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 227 197 385
EPS ($) 3.80 4.26 9.42
EPS without NRI ($) 3.80 4.26 9.42
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}